Novartis Drug Patent Portfolio

Novartis owns 53 orange book drugs protected by 287 US patents with Alomide having the least patent protection, holding only 1 patent. And Promacta with maximum patent protection, holding 28 patents. Given below is the list of Novartis's drug patents along with their expiration dates.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US12208102	Methods of treating cancer	18 Sep, 2041	Active
US11951101	Methods of using factor B inhibitors	15 Jul, 2041	Active
US11603363	Crystalline form of LNP023	25 May, 2041	Active
US11407735	Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide	14 May, 2040	Active
US11504333	Pharmaceutical composition	29 Dec, 2038	Active
US11723901	Uses of piperidinyl-indole derivatives	30 Aug, 2038	Active
US11504333	Pharmaceutical composition	29 Jun, 2038	Active
US10722471	Galenic formulations of organic compounds	02 Feb, 2037	Active
US10851377	Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder	25 Aug, 2036	Active
US11944602	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker	24 Jul, 2036	Active
US10799506	Ribociclib tablet	14 Apr, 2036	Active
US12064434	Ribociclib tablet	14 Apr, 2036	Active
US12109277	Apparatus and method for penetrating and enlarging adjacent tissue layers	09 Mar, 2036	Active
US11951190	Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer	12 Nov, 2035	Active
US10398791	Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer	17 Oct, 2034	Active
US10125369	PCSK9 iRNA compositions and methods of use thereof	18 Aug, 2034	Active
US10093663	Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof	14 Jul, 2034	Active
US9682968	Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof	14 Jul, 2034	Active
US10869869	Method of adjuvant cancer treatment	28 Feb, 2034	Active
US10869869	Method of adjuvant cancer treatment	30 Aug, 2033	Active
US8829195	Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1	13 May, 2033	Active
US8227462	Pyrrolidine-1,2-dicarboxamide derivatives	29 Apr, 2033	Active
US9061029	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	07 Oct, 2032	Active
US9592208	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	30 Sep, 2032	Active
US8580304	Pharmaceutical composition	28 Jul, 2032	Active
US9155706	Pharmaceutical composition	28 Jul, 2032	Active
US9271941	Pharmaceutical composition	28 Jul, 2032	Active
US9399021	Pharmaceutical composition	28 Jul, 2032	Active
US9061029	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	07 Apr, 2032	Active
US9592208	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	30 Mar, 2032	Active
US8703787	Methods of using ALK inhibitors	02 Feb, 2032	Active
US8580304	Pharmaceutical composition	28 Jan, 2032	Active
US9155706	Pharmaceutical composition	28 Jan, 2032	Active
US9271941	Pharmaceutical composition	28 Jan, 2032	Active
US9399021	Pharmaceutical composition	28 Jan, 2032	Active
US9309229	Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine	18 Jan, 2032	Active
US12071402	Immunosuppressant formulations	05 Jan, 2032	Active
US9193732	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	09 Nov, 2031	Active
US9868739	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	09 Nov, 2031	Active
US8703781	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	15 Apr, 2031	Active
US8952018	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	15 Apr, 2031	Active
US8415355	Pyrrolopyrimidine compounds and their uses	13 Mar, 2031	Active
US8575146	Pharmaceutical uses of staurosporine derivatives	02 Dec, 2030	Active
US8492441	Dosage regimen of an S1P receptor agonist	30 Nov, 2030	Active
US8703781	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	15 Oct, 2030	Active
US8952018	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	15 Oct, 2030	Active
US7994185	Benzene sulfonamide thiazole and oxazole compounds	20 Jul, 2030	Active
US8415345	Benzene sulfonamide thiazole and oxazole compounds	20 Jul, 2030	Active
US8039474	2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists	29 Jun, 2030	Active
US8039479	Compounds and compositions as protein kinase inhibitors	29 Jun, 2030	Active
US8685980	Pyrrolopyrimidine compounds and their uses	25 May, 2030	Active
US7994185	Benzene sulfonamide thiazole and oxazole compounds	20 Jan, 2030	Active
US8415345	Benzene sulfonamide thiazole and oxazole compounds	20 Jan, 2030	Active
US8613949	Galenical formulations of organic compounds	21 Dec, 2029	Active
US8106022	Carbohydrate conjugates as delivery agents for oligonucleotides	12 Dec, 2029	Active
US8962630	Pyrrolopyrimidine compounds and their uses	09 Dec, 2029	Active
US9233956	Benzene sulfonamide thiazole and oxazole compounds	04 Nov, 2029	Active
US8178582	Pharmaceutical compositions having desirable bioavailability	10 Oct, 2029	Active
US8722735	Pharmaceutical compositions having desirable bioavailability	10 Oct, 2029	Active
US8821927	Pharmaceutical composition	18 Sep, 2029	Active
US8476268	Pyrrolidine-1,2-dicarboxamide derivatives	10 Sep, 2029	Active
US9416136	Pyrrolopyrimidine compounds and their uses	20 Aug, 2029	Active
US8754123	Pharmaceutical compositions having desirable bioavailability	19 May, 2029	Active
US9233956	Benzene sulfonamide thiazole and oxazole compounds	04 May, 2029	Active
US9144561	Pharmaceutical compositions having desirable bioavailability	13 Mar, 2029	Active
US8163904	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide	23 Feb, 2029	Active
US10806791	Carbohydrate conjugates as delivery agents for oligonucleotides	04 Dec, 2028	Active
US8828956	Carbohydrate conjugates as delivery agents for oligonucleotides	04 Dec, 2028	Active
US9370582	Carbohydrate conjugates as delivery agents for oligonucleotides	04 Dec, 2028	Active
US8182838	Dry powder composition comprising co-jet milled particles for pulmonary inhalation	20 Oct, 2028	Active
US8479730	Inhaler device	11 Oct, 2028	Active
US7973031	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity	09 Oct, 2028	Active
US7939519	Immunosuppresant compounds and compositions	27 Aug, 2028	Active
US10131907	Glycoconjugates of RNA interference agents	24 Aug, 2028	Active
US8163904	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide	23 Aug, 2028	Active
US11369590	PSMA binding ligand-linker conjugates and methods for using	15 Aug, 2028	Active
US10406240	PSMA binding ligand-linker conjugates and methods for using	15 Aug, 2028	Active
US11318121	PSMA binding ligand-linker conjugates and methods for using	15 Aug, 2028	Active
US9006224	Neuroendocrine tumor treatment	01 Jul, 2028	Active
US8324225	Pyrrolopyrimidine compounds and their uses	17 Jun, 2028	Active
US7964592	2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders	29 Apr, 2028	Active
US8293756	Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate	25 Mar, 2028	Active
US7932241	Pharmaceutical products comprising bisphosphonates	05 Feb, 2028	Active
US8052993	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028	Active
US8052994	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028	Active
US8052995	3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028	Active
US8062665	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028	Active
US8071129	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028	Active
US8828430	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028	Active
US8222222	Compositions and methods for inhibiting expression of the PCSK9 gene	29 Dec, 2027	Active
US10543179	Dosage regimen of an S1P receptor modulator	25 Dec, 2027	Active
US9187405	S1P receptor modulators for treating relasping-remitting multiple sclerosis	25 Dec, 2027	Active
US7378423	Pyrimidine compound and medical use thereof	29 Nov, 2027	Active
US8377921	Compounds and compositions as protein kinase inhibitors	20 Nov, 2027	Active
US8399450	Compounds and compositions as protein kinase inhibitors	20 Nov, 2027	Active
US8293756	Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate	25 Sep, 2027	Active
US8052993	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027	Active
US8052994	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027	Active
US8052995	3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027	Active
US8062665	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027	Active
US8071129	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027	Active
US8828430	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027	Active
US9187405	S1P receptor modulators for treating relasping-remitting multiple sclerosis	25 Jun, 2027	Active
US7378423	Pyrimidine compound and medical use thereof	29 May, 2027	Active
US8877938	Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations	27 May, 2027	Active
US8809292	Compositions and methods for inhibiting expression of the PCSK9 gene	10 May, 2027	Active
US8389537	Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	18 Jan, 2027	Active
US8415363	Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	18 Jan, 2027	Active
US8501760	Pharmaceutical compositions comprising nilotinib or its salt	18 Jan, 2027	Active
US9388134	Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations	08 Nov, 2026	Active
US8324283	Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol	29 Sep, 2026	Active
US8389537	Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	18 Jul, 2026	Active
US8415363	Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	18 Jul, 2026	Active
US8501760	Pharmaceutical compositions comprising nilotinib or its salt	18 Jul, 2026	Active
US8168616	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension	03 Jul, 2026	Active
US8410131	Cancer treatment	01 May, 2026	Active
US7893074	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders	25 Apr, 2026	Active
US8324283	Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol	29 Mar, 2026	Active
US7547719	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	13 Jan, 2026	Active
US8835443	Pyrimidine compound and medical use thereof	10 Dec, 2025	Active
US8324189	Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases	29 Nov, 2025	Active
US8410131	Cancer treatment	01 Nov, 2025	Active
US7547719	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	13 Jul, 2025	Active
US8835443	Pyrimidine compound and medical use thereof	10 Jun, 2025	Active
US8324189	Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases	29 May, 2025	Active
US6878721	Beta2-adrenoceptor agonists	25 Feb, 2025	Expired
US8101659	Methods of treatment and pharmaceutical composition	15 Jan, 2025	Expired
US11530408	Therapeutic compositions	18 May, 2024	Expired
US10273477	Therapeutic compositions	08 Mar, 2024	Expired
US10669544	Therapeutic compositions	08 Mar, 2024	Expired
US9708615	Therapeutic compositions	08 Mar, 2024	Expired
US7169791	Inhibitors of tyrosine kinases	04 Jan, 2024	Expired
US9708610	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	01 Jan, 2024	Expired
US7795293	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	21 Nov, 2023	Expired
US8475839	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same	16 Nov, 2023	Expired
US10266825	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	04 Nov, 2023	Expired
US11078485	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	04 Nov, 2023	Expired
US7105530	Pyrimidineamines as angiogenesis modulators	19 Oct, 2023	Expired
US7589079	Crystalline and amorphous forms of beta-L-2′-deoxythymidine	11 Sep, 2023	Expired
US7858594	Crystalline and amorphous forms of beta-L-2′-deoxythymidine	11 Sep, 2023	Expired
US7977376	Olopatadine formulations for topical nasal administration	02 Aug, 2023	Expired
US7169791	Inhibitors of tyrosine kinases	04 Jul, 2023	Expired
US7795293	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	21 May, 2023	Expired
US7160870	Thrombopoietin mimetics	20 May, 2023	Expired
US8183295	Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic	16 May, 2023	Expired
US8101599	Pharmaceutical composition containing anti-hypertensive agents	16 May, 2023	Expired
US8475839	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same	16 May, 2023	Expired
US8399508	Olopatadine formulations for topical nasal administration	17 Mar, 2023	Expired
US8232383	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)	20 Feb, 2023	Expired
US7977376	Olopatadine formulations for topical nasal administration	02 Feb, 2023	Expired
US8188276	2,4-pyrimidinediamine compounds and their uses	31 Jan, 2023	Expired
US8835430	2,4-pyrimidinediamine compounds and their uses	31 Jan, 2023	Expired
US9018204	2,4-pyrimidinediamine compounds and their uses	31 Jan, 2023	Expired
US9416112	2,4-pyrimidinediamine compounds and their uses	31 Jan, 2023	Expired
US7160870	Thrombopoietin mimetics	20 Nov, 2022	Expired
US8222244	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity	29 Oct, 2022	Expired
US8399508	Olopatadine formulations for topical nasal administration	17 Sep, 2022	Expired
US8436010	Treatment of solid tumors with rapamycin derivatives	22 Aug, 2022	Expired
US8778962	Treatment of solid tumors with rapamycin derivatives	18 Aug, 2022	Expired
US10590418	Methods and compositions for RNAi mediated inhibition of gene expression in mammals	19 Jul, 2022	Expired
US6958335	Treatment of gastrointestinal stromal tumors	19 Jun, 2022	Expired
US8546143	Compositions and methods for inhibiting expression of a target gene	23 Apr, 2022	Expired
US9074213	Compositions and methods for inhibiting expression of a target gene	09 Mar, 2022	Expired
US8436010	Treatment of solid tumors with rapamycin derivatives	22 Feb, 2022	Expired
US8778962	Treatment of solid tumors with rapamycin derivatives	18 Feb, 2022	Expired
US6958335	Treatment of gastrointestinal stromal tumors	19 Dec, 2021	Expired
US7262203	Pyrimidineamines as angiogenesis modulators	19 Dec, 2021	Expired
US8114885	Chemical compounds	19 Dec, 2021	Expired
US7332481	Thrombopoietin mimetics	24 Nov, 2021	Expired
US7452874	Thrombopoietin mimetics	24 Nov, 2021	Expired
US7473686	Thrombopoietin mimetics	24 Nov, 2021	Expired
US7790704	Thrombopoietin mimetics	24 Nov, 2021	Expired
US7157466	Quinazoline ditosylate salt compounds	19 Nov, 2021	Expired
US8618174	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	15 Nov, 2021	Expired
US7736670	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021	Expired
US8048451	Pharmaceutical compositions for inhalation	27 Jun, 2021	Expired
US8303991	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021	Expired
US8435567	Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation	27 Jun, 2021	Expired
US8580306	Particles for use in a pharmaceutical composition	27 Jun, 2021	Expired
US8956661	Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof	27 Jun, 2021	Expired
US9931304	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021	Expired
US9962338	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021	Expired
US8119148	Suspension comprising oxcarbazepine	19 Jun, 2021	Expired
US7332481	Thrombopoietin mimetics	24 May, 2021	Expired
US7452874	Thrombopoietin mimetics	24 May, 2021	Expired
US7473686	Thrombopoietin mimetics	24 May, 2021	Expired
US7790704	Thrombopoietin mimetics	24 May, 2021	Expired
US7229607	Treatment of respiratory disease	09 Apr, 2021	Expired
US8029768	Treatment of respiratory diseases	09 Apr, 2021	Expired
US7153964	Pyrimidine compounds	26 Feb, 2021	Expired
US8119148	Suspension comprising oxcarbazepine	19 Dec, 2020	Expired
US6887459	Aerosol composition comprising formoterol	28 Nov, 2020	Expired
US6569837	β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B	25 Oct, 2020	Expired
US6713485	Heterocyclic compounds	29 Sep, 2020	Expired
US6559188	Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes	15 Sep, 2020	Expired
US6878749	Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes	15 Sep, 2020	Expired
US7297703	Macrolides	06 Jun, 2020	Expired
US8067437	Beta-2-adrenoreceptor agonists	02 Jun, 2020	Expired
US8658673	BETA2-adrenoreceptor agonists	02 Jun, 2020	Expired
US8796307	Beta2-adrenoreceptor agonists	02 Jun, 2020	Expired
US7820694	Beta-2-adrenoreceptor agonists	02 Jun, 2020	Expired
US8283362	Beta-2-adrenoreceptor agonists	02 Jun, 2020	Expired
US5665772	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	09 Mar, 2020	Expired
US7297703	Macrolides	06 Dec, 2019	Expired
US7741338	Macrolides	06 Dec, 2019	Expired
US6894051	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	23 Nov, 2019	Expired
US5665772	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	09 Sep, 2019	Expired
US5604229	2-amino-1,3-propanediol compound and immunosuppressant	18 Aug, 2019	Expired
US6395716	β-L-2′-deoxy-nucleosides for the treatment of hepatitis B	10 Aug, 2019	Expired
US6444652	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B	10 Aug, 2019	Expired
US6566344	β-L-2′-deoxy-nucleosides for the treatment of hepatitis B	10 Aug, 2019	Expired
US7795238	β-L-2′-deoxy-nucleosides for the treatment of hepatitis B	10 Aug, 2019	Expired
US7544799	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jul, 2019	Expired
USRE43932	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jul, 2019	Expired
US6395728	Method of treatment and pharmaceutical composition	08 Jul, 2019	Expired
US6894051	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	23 May, 2019	Expired
US6280959	Metal complexes	30 Apr, 2019	Expired
US6465504	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	05 Apr, 2019	Expired
US6488027	Powder inhaler	08 Mar, 2019	Expired
US5604229	2-amino-1,3-propanediol compound and immunosuppressant	18 Feb, 2019	Expired
US7544799	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jan, 2019	Expired
USRE43932	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jan, 2019	Expired
US6727256	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors	08 Jan, 2019	Expired
US8513262	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors	08 Jan, 2019	Expired
US6280959	Metal complexes	30 Oct, 2018	Expired
US7037525	Oxacarbazepine film-coated tablets	12 Aug, 2018	Expired
US5559111	δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides	21 Jul, 2018	Expired
US6528678	Phosgene-free process for preparing carbamates	24 Apr, 2018	Expired
US6582678	Carrier particles for use in dry powder inhalers	24 Apr, 2018	Expired
US6306900	Enteric coated pharmaceutical compositions	27 Feb, 2018	Expired
US7037525	Oxacarbazepine film-coated tablets	12 Feb, 2018	Expired
US6239124	Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin	11 Feb, 2018	Expired
US6455518	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin	29 Jan, 2018	Expired
US6294197	Solid oral dosage forms of valsartan	18 Dec, 2017	Expired
US6641841	Tablet composition	14 Nov, 2017	Expired
US6844008	Tablet composition	14 Nov, 2017	Expired
US6004565	Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties	23 Sep, 2017	Expired
US6239124	Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin	11 Aug, 2017	Expired
US6455518	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin	29 Jul, 2017	Expired
US6391874	Fused heterocyclic compounds as protein tyrosine kinase inhibitors	11 Jul, 2017	Expired
US6828320	Heterocyclic compounds	11 Jul, 2017	Expired
US6596750	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	24 Jun, 2017	Expired
US6294197	Solid oral dosage forms of valsartan	18 Jun, 2017	Expired
US5972990	Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims	26 Apr, 2017	Expired
US6025391	Enteric-coated pharmaceutical compositions of mycophenolate	10 Apr, 2017	Expired
US6172107	Entric-coated pharmaceutical compositions	10 Apr, 2017	Expired
US5922338	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	13 Jan, 2017	Expired
US5922682	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	13 Jan, 2017	Expired
US6004973	Pharmaceutical compositions comprising rafamycin coprecipitates	12 Jan, 2017	Expired
US5972990	Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims	26 Oct, 2016	Expired
US5922338	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	13 Jul, 2016	Expired
US5922682	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	13 Jul, 2016	Expired
US6004973	Pharmaceutical compositions comprising rafamycin coprecipitates	12 Jul, 2016	Expired
US5840763	Treatment of a latent infection of herpes viruses	01 Mar, 2016	Expired
US5916893	Treatment of a latent infection of herpes virus	01 Mar, 2016	Expired
US6521260	Carrier particles for use in dry powder inhalers	31 Jan, 2016	Expired
US5753618	Somatostatin analogue composition and use in treating breast cancer	19 Nov, 2015	Expired
US5840763	Treatment of a latent infection of herpes viruses	01 Sep, 2015	Expired
US5916893	Treatment of a latent infection of herpes virus	01 Sep, 2015	Expired
US5521184	Pyrimidine derivatives and processes for the preparation thereof	04 Jul, 2015	Expired
US5753618	Somatostatin analogue composition and use in treating breast cancer	19 May, 2015	Expired
US5688530	Sustained release formulations of water soluble peptides	18 May, 2015	Expired
US5866581	Penciclovir for the treatment of post therapeutic neuralgia	04 Apr, 2015	Expired
US6124304	Penciclovir for the treatment of zoster associated pain	04 Apr, 2015	Expired
US5521184	Pyrimidine derivatives and processes for the preparation thereof	04 Jan, 2015	Expired
US5639480	Sustained release formulations of water soluble peptides	17 Dec, 2014	Expired
US5688530	Sustained release formulations of water soluble peptides	18 Nov, 2014	Expired
US5677331	Antimalarial compositions	14 Oct, 2014	Expired
US5866581	Penciclovir for the treatment of post therapeutic neuralgia	04 Oct, 2014	Expired
US6124304	Penciclovir for the treatment of zoster associated pain	04 Oct, 2014	Expired
US5985321	Soft gelatin capsule manufacture	26 Sep, 2014	Expired
US5639480	Sustained release formulations of water soluble peptides	17 Jun, 2014	Expired
US6440990	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	24 Mar, 2014	Expired
US5602176	Phenyl carbamate	11 Feb, 2014	Expired
US5538739	Sustained release formulations of water soluble peptides	23 Jan, 2014	Expired
US5441958	Ophthalmic compositions comprising emedastine and methods for their use	08 Dec, 2013	Expired
US6440990	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	24 Sep, 2013	Expired
US5538739	Sustained release formulations of water soluble peptides	23 Jul, 2013	Expired
US4939130	Substituted alkanediphosphonic acids and pharmaceutical use	02 Mar, 2013	Expired
US5488150	Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them	30 Jan, 2013	Expired
US5463116	Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them	21 Oct, 2012	Expired
US5457126	Use of lodoxamide to treat ophthalmic allergic conditions	10 Oct, 2012	Expired
US5399578	Acyl compounds	21 Sep, 2012	Expired
US4939130	Substituted alkanediphosphonic acids and pharmaceutical use	02 Sep, 2012	Expired
US5442049	Oligonucleotides for modulating the effects of cytomegalovirus infections	15 Aug, 2012	Expired
US5595978	Composition and method for treatment of CMV retinites	15 Aug, 2012	Expired
US4948807	Phenyl carbamates	14 Aug, 2012	Expired

Latest Legal Activities on Novartis's Drug Patents

Given below is the list of recent legal activities going on the following drug patents of Novartis.

Activity	Date	Patent Number

Expire Patent Critical	01 Jul, 2024	US8188276 (Litigated)
Maintenance Fee Reminder Mailed Critical	24 Jun, 2024	US8303991 (Litigated)
Maintenance Fee Reminder Mailed Critical	24 Jun, 2024	US8303991 (Litigated)
Expire Patent Critical	24 Jun, 2024	US8183295
Surcharge for Late Payment, Large Entity	11 Jun, 2024	US10806791
Payment of Maintenance Fee, 4th Year, Large Entity	11 Jun, 2024	US10806791
Maintenance Fee Reminder Mailed Critical	10 Jun, 2024	US10806791
Payment of Maintenance Fee, 4th Year, Large Entity	05 Jun, 2024	US10869869
Expire Patent Critical	03 Jun, 2024	US8168616
Payment of Maintenance Fee, 4th Year, Large Entity	03 Jun, 2024	US10851377
Maintenance Fee Reminder Mailed Critical	27 May, 2024	US8283362
Payment of Maintenance Fee, 12th Year, Large Entity	22 May, 2024	US8324189
Payment of Maintenance Fee, 12th Year, Large Entity	22 May, 2024	US8324225
Payment of Maintenance Fee, 12th Year, Large Entity	22 May, 2024	US8324225
Expire Patent Critical	22 Apr, 2024	US10590418

Novartis's Drug Patent Litigations

Novartis's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 05, 1995, against patent number US5922682. The petitioner , challenged the validity of this patent, with BRICH et al as the respondent. Click below to track the latest information on how companies are challenging Novartis's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8101659	August, 2020	Terminated-Denied (16 Feb, 2021)	Novartis Pharmaceuticals Corporation	Biocon Pharma Limited
US9006224	July, 2016	Final Written Decision (05 Oct, 2020)	Novartis AG	Par Pharmaceutical, Inc. et al.
US8410131	June, 2017	Terminated-Settled (03 Jun, 2019)	Novartis Pharmaceuticals Corporation	Breckenridge Pharmaceutial, Inc.
US8410131	January, 2018	Terminated-Settled (03 Jun, 2019)	Novartis Pharmaceuticals Corporation	Hikma Pharmaceuticals PLC
US9187405	August, 2017	FWD Entered (07 Aug, 2018)	Novartis Pharmaceuticals Corporation	Actavis Elizabeth LLC
US9187405	August, 2017	Terminated (07 Aug, 2018)	Novartis Pharmaceuticals Corporation	Sun Pharmaceutical Industries, Ltd. et al.
US9187405	February, 2017	FWD Entered (11 Jul, 2018)	Novartis AG	Apotex Inc.
US5665772	October, 2015	FWD Entered (11 Jan, 2018)	Novartis AG	Par Pharmaceutical, Inc.
US9006224	March, 2017	Final Written Decision (25 Sep, 2017)	Novartis AG	Argentum Pharmaceuticals LLC et al.
US9006224	March, 2017	Terminated-Settled (25 Sep, 2017)	Novartis AG	West-Ward Pharmaceuticals International Limited
US9187405	June, 2017	FWD Entered (17 Aug, 2017)	Novartis AG	Argentum Pharmaceuticals LLC
US9006224	July, 2016	Terminated-Denied (13 Feb, 2017)	Novartis AG	Roxane Laboratories, Inc.
US5665772	May, 2016	FWD Entered (27 Oct, 2016)	Novartis AG	BRECKENRIDGE PHARMACEUTICAL, INC.
US5665772	May, 2016	Terminated-Denied (27 Oct, 2016)	Novartis AG	Par Pharmaceutical, Inc.
US5665772	May, 2016	FWD Entered (27 Oct, 2016)	Novartis AG	Roxane Laboratories, Inc.
US5665772	May, 2016	Terminated-Denied (27 Oct, 2016)	Novartis AG	Breckenridge Pharmaceutical, Inc.
US6455518	October, 2015	Terminated-Denied (28 Apr, 2016)	Novartis AG	Par Pharmaceutical, Inc.
US7297703	October, 2015	Terminated-Denied (01 Apr, 2016)	Novartis AG	Par Pharmaceutical, Inc.
US7741338	October, 2015	Terminated-Denied (01 Apr, 2016)	Novartis AG	Par Pharmaceutical, Inc.
US8324283	May, 2014	FWD Entered (24 Sep, 2015)	Novartis AG	TORRENT PHARMACEUTICALS LIMITED
US8324283	December, 2014	Final Written Decision (24 Sep, 2015)	Novartis AG et al.	Apotex, Inc. et al.
US10590418	April, 2012	Decision (04 Mar, 2015)	Mark A. Kay et al
US8575146	January, 2011	Decision (22 Mar, 2013)	Steven Coutre
US6894051	March, 2003	Decision (24 Nov, 2003)	JURG ZIMMERMANN et al
US5972990	January, 1	Decision (12 Feb, 1999)	PFEFFER et al
US5922682	April, 1995	Decision (04 Jul, 1776)	BRICH et al

Novartis Drug Patents' Oppositions Filed in EPO

Novartis drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 20, 2003, by Sirna Therapeutics, Inc.. This opposition was filed on patent number EP00910510A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status

EP15177166A	May, 2023	Synthon BV	Granted and Under Opposition
EP19174594A	May, 2023	Brand Murray Fuller LLP	Granted and Under Opposition
EP15177166A	May, 2023	Wuesthoff & Wuesthoff Patentanwälte PartG mbB	Granted and Under Opposition
EP19174594A	May, 2023	STADA Arzneimittel AG	Granted and Under Opposition
EP15177166A	Mar, 2023	neuraxpharm Arzneimittel GmbH	Granted and Under Opposition
EP15177166A	Jan, 2023	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP15177166A	Jan, 2023	BIOGARAN	Granted and Under Opposition
EP15177166A	Jan, 2023	STADA Arzneimittel AG	Granted and Under Opposition
EP18155722A	Jan, 2023	Generics [UK] Limited	Granted and Under Opposition
EP18155722A	Jan, 2023	Ethypharm	Granted and Under Opposition
EP18155722A	Jan, 2023	STADA Arzneimittel AG	Granted and Under Opposition
EP15177166A	Jan, 2023	Bausch Health Ireland Limited	Granted and Under Opposition
EP15177166A	Dec, 2022	Vivanta Generics s.r.o. / MSN Labratories Private Ltd.	Granted and Under Opposition
EP15177166A	Dec, 2022	Heumann Pharma GmbH & Co. Generica KG	Granted and Under Opposition
EP15177166A	Dec, 2022	Accord Healthcare Ltd	Granted and Under Opposition
EP15177166A	Nov, 2022	A-med GmbH	Granted and Under Opposition
EP15177166A	Nov, 2022	RAFARM S.A.	Granted and Under Opposition
EP15177166A	Nov, 2022	Genepharm S.A.	Granted and Under Opposition
EP15177166A	Oct, 2022	Elpen Pharmaceutical Co. Inc.	Granted and Under Opposition
EP15177166A	Oct, 2022	Glenmark Pharmaceuticals Europe Ltd.	Granted and Under Opposition
EP15177166A	Oct, 2022	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP15177166A	Oct, 2022	Generics [UK] Limited	Granted and Under Opposition
EP15177166A	Oct, 2022	Zentiva k.s.	Granted and Under Opposition
EP15177166A	Oct, 2022	PHARMATHEN S.A.	Granted and Under Opposition
EP13835019A	Jun, 2022	Generics [UK] Limited	Granted and Under Opposition
EP13835019A	Jun, 2022	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP13835019A	Jun, 2022	STADA Arzneimittel AG	Granted and Under Opposition
EP10176094A	Apr, 2021	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP10176094A	Apr, 2021	betapharm Arzneimittel GmbH	Granted and Under Opposition
EP10176094A	Apr, 2021	Krka, d.d., Novo mesto	Granted and Under Opposition
EP10176094A	Apr, 2021	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP10176094A	Apr, 2021	STADA Arzneimittel AG	Granted and Under Opposition
EP10176094A	Apr, 2021	D Young & Co LLP	Granted and Under Opposition
EP10176094A	Apr, 2021	Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi	Granted and Under Opposition
EP11849974A	Apr, 2021	Generics [UK] Limited	Granted and Under Opposition
EP11849974A	Apr, 2021	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP10176094A	Jan, 2021	Generics [UK] Limited	Granted and Under Opposition
EP08798020A	Jul, 2020	Boult Wade Tennant LLP	Revoked
EP08798020A	Jul, 2020	Orano Med	Revoked
EP18155724A	Jun, 2020	ARROW GENERIQUES	Granted and Under Opposition
EP18155724A	May, 2020	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP18155724A	May, 2020	Zentiva k.s.	Granted and Under Opposition
EP18155724A	May, 2020	Generics [UK] Ltd	Granted and Under Opposition
EP18155724A	Apr, 2020	PUREN Pharma GmbH & Co. KG	Granted and Under Opposition
EP10824148A	Mar, 2020	Generics (UK) Ltd	Opposition rejected
EP10824148A	Mar, 2020	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP18155644A	Feb, 2020	ARROW GENERIQUES	Granted and Under Opposition
EP18155644A	Feb, 2020	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP18155644A	Feb, 2020	Generics [UK] Limited	Granted and Under Opposition
EP18155724A	Feb, 2020	Ethypharm	Granted and Under Opposition
EP18155644A	Jan, 2020	Dr. Reddy's Laboratories Limited	Granted and Under Opposition
EP18155724A	Sep, 2019	BIOGARAN	Granted and Under Opposition
EP18155644A	Sep, 2019	Zentiva Pharma GmbH	Granted and Under Opposition
EP16186041A	Sep, 2019	STADA Arzneimittel AG	Granted and Under Opposition
EP16186041A	Sep, 2019	Generics [UK] Ltd	Granted and Under Opposition
EP16186041A	Sep, 2019	Accord Healthcare Ltd	Granted and Under Opposition
EP16186041A	Sep, 2019	Zentiva k.s.	Granted and Under Opposition
EP16186041A	Aug, 2019	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP16186041A	Aug, 2019	Synthon B.V.	Granted and Under Opposition
EP18155724A	Aug, 2019	Dr. Reddy's Laboratories / Betapharm Arzneimittel GmbH	Granted and Under Opposition
EP18155724A	Aug, 2019	Accord Healthcare Ltd	Granted and Under Opposition
EP18155724A	Aug, 2019	STADA Arzneimittel AG	Granted and Under Opposition
EP18155644A	Jul, 2019	Accord Healthcare Ltd	Granted and Under Opposition
EP10174983A	Jul, 2019	Zentiva France	Revoked
EP18155644A	Jul, 2019	Ethypharm	Granted and Under Opposition
EP18155644A	Jul, 2019	BIOGARAN	Granted and Under Opposition
EP16186041A	Jun, 2019	Ethypharm	Granted and Under Opposition
EP18155644A	May, 2019	STADA Arzneimittel AG	Granted and Under Opposition
EP16167355A	May, 2019	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP16167355A	Apr, 2019	Generics (UK) Ltd	Opposition rejected
EP04727320A	Dec, 2018	Teva UK Limited	Revoked
EP10181354A	Dec, 2018	Teva UK Limited	Patent maintained as amended
EP11806079A	Apr, 2018	Generics (UK) Ltd	Revoked
EP11806079A	Apr, 2018	Teva Pharmaceutical Industries Ltd	Revoked
EP14164259A	Mar, 2018	Generics (UK) Ltd	Revoked
EP15202422A	Feb, 2018	actrevo GmbH	Granted and Under Opposition
EP15202422A	Feb, 2018	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP15202422A	Feb, 2018	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP15202422A	Feb, 2018	Bausch & Lomb Incorporated	Granted and Under Opposition
EP15202422A	Feb, 2018	Instone, Terry/Appleyard Lees IP LLP/Read, Howard	Granted and Under Opposition
EP12193597A	Jan, 2018	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP12193597A	Jan, 2018	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP14164565A	Dec, 2017	Generics (U.K.) Limited	Revoked
EP14164565A	Dec, 2017	Ethypharm	Revoked
EP06025389A	Dec, 2017	Silence Therapeutics GmbH	Revoked
EP10173956A	Nov, 2017	D Young & Co LLP	Patent maintained as amended
EP10174985A	Apr, 2017	Intas Pharmaceuticals Ltd.	Revoked
EP10174985A	Apr, 2017	Generics [UK] Ltd	Revoked
EP10174985A	Apr, 2017	Wittkopp, Alexander	Revoked
EP10174985A	Apr, 2017	STADA Arzneimittel AG	Revoked
EP10174985A	Apr, 2017	Teva Pharmaceutical Industries Ltd	Revoked
EP10174985A	Apr, 2017	KRKA, d.d., Novo mesto	Revoked
EP10174985A	Apr, 2017	Fresenius Kabi Deutschland GmbH	Revoked
EP10174985A	Apr, 2017	Synthon Biopharmaceuticals B.V.	Revoked
EP10011217A	Apr, 2017	Silence Therapeutics GmbH	Opposition rejected
EP09743378A	Dec, 2016	STADA Arzneimittel AG	Opposition rejected
EP10781781A	Nov, 2016	Generics (U.K.) Limited	Granted and Under Opposition
EP10781781A	Nov, 2016	Hamm&Wittkopp Patentanwälte PartmbB	Granted and Under Opposition
EP10781781A	Nov, 2016	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP10781781A	Nov, 2016	Intas Pharmaceuticals Ltd.	Granted and Under Opposition
EP10781781A	Nov, 2016	Fresenius Kabi Deutschland GmbH	Granted and Under Opposition
EP07840632A	Sep, 2016	Galenicum Health S.L.	Revoked
EP07840632A	Sep, 2016	Generics (U.K.) Limited	Revoked
EP07840632A	Sep, 2016	Teva Pharmaceutical Industries Ltd	Revoked
EP07840632A	Sep, 2016	Alfred E. Tiefenbacher (GmbH & Co. KG)	Revoked
EP07840632A	Sep, 2016	ZBM Patents ApS	Revoked
EP07820560A	Jun, 2016	Fresenius Kabi Deutschland GmbH	Patent maintained as amended
EP07820560A	Jun, 2016	medac Gesellschaft für klinische Spezialpräparate mbH	Patent maintained as amended
EP07820560A	Jun, 2016	Strawman Limited	Patent maintained as amended
EP07820560A	Jun, 2016	Generics [UK] Limited	Patent maintained as amended
EP12703670A	Mar, 2016	Generics [UK] Limited	Opposition rejected
EP12703670A	Mar, 2016	I P S Intellectual Property Services	Opposition rejected
EP12703670A	Mar, 2016	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP09722278A	Feb, 2016	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP10174983A	Feb, 2016	STADA Arzneimittel AG	Revoked
EP10174983A	Feb, 2016	Actavis PTC ehf	Revoked
EP10174983A	Feb, 2016	Wittkopp, Alexander	Revoked
EP10174983A	Feb, 2016	Synthon B.V.	Revoked
EP10174983A	Feb, 2016	Intas Pharmaceuticals Ltd.	Revoked
EP10174983A	Feb, 2016	Generics [UK] Limited	Revoked
EP10174983A	Feb, 2016	Ethypharm	Revoked
EP10174983A	Feb, 2016	Teva Pharmaceutical Industries Ltd	Revoked
EP09722278A	Feb, 2016	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP09722278A	Feb, 2016	Pohlman, Sandra M.	Granted and Under Opposition
EP10008929A	Oct, 2015	Quark Pharmaceuticals, Inc.	Patent maintained as amended
EP10175197A	Jan, 2015	Maiwald Patentanwalts GmbH	Revoked
EP10175197A	Jan, 2015	Ethypharm	Revoked
EP10175197A	Jan, 2015	Generics [UK] Limited (trading as Mylan)	Revoked
EP10175197A	Jan, 2015	Synthon B.V./Genthon B.V.	Revoked
EP10175197A	Jan, 2015	Teva Pharmaceutical Industries Ltd.	Revoked
EP06827689A	Oct, 2014	Maiwald Patentanwalts GmbH	Revoked
EP01935167A	Jan, 2014	Taylor Wessing LLP	Revoked
EP01935167A	Jan, 2014	BIOGARAN	Revoked
EP01935167A	Jan, 2014	Accord Healthcare Ltd	Revoked
EP01935167A	Jan, 2014	Synthon B.V.	Revoked
EP01935167A	Jan, 2014	Sanovel IIaç San. ve Tic. A.S.	Revoked
EP01935167A	Dec, 2013	Genericon Pharma Gesellschaft m.b.H.	Revoked
EP01935167A	Nov, 2013	STADA Arzneimittel AG	Revoked
EP01935167A	Sep, 2013	PFIZER LIMITED	Revoked
EP01935167A	Sep, 2013	Hikma Pharma GmbH	Revoked
EP01935167A	Aug, 2013	Fresenius Kabi Deutschland GmbH	Revoked
EP10008931A	Jul, 2013	Alnylam Pharmaceuticals Inc.	Opposition procedure closed
EP03716126A	Jul, 2013	Alnylam Pharmaceuticals Inc.	Opposition procedure closed
EP01935167A	Jun, 2013	medac Gesellschaft für klinische Spezialpräparate mbH	Revoked
EP01935167A	Jun, 2013	Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH	Revoked
EP10008930A	May, 2013	Quark Pharmaceuticals, Inc.	Patent maintained as amended
EP10008930A	May, 2013	Alnylam Pharmaceuticals Inc.	Patent maintained as amended
EP01935167A	May, 2013	CHEMI SPA	Revoked
EP01935167A	May, 2013	Actavis Group Ptc Ehf	Revoked
EP01935167A	May, 2013	hameln rds gmbh	Revoked
EP01935167A	Apr, 2013	Teva Pharmaceutical Industries LTD.	Revoked
EP01935167A	Apr, 2013	Generics [UK] Limited	Revoked
EP06800109A	Mar, 2013	Actavis Group Ptc Ehf	Revoked
EP06800109A	Mar, 2013	D YOUNG & CO	Revoked
EP04768542A	Aug, 2012	Teva UK Limited	Revoked
EP03743684A	Jun, 2011	Alcon Research, Ltd.	Patent maintained as amended
EP03743684A	May, 2011	Dharmacon, Inc.	Patent maintained as amended
EP03743684A	May, 2011	Alnylam Pharmaceuticals Inc.	Patent maintained as amended
EP03743684A	May, 2011	Novartis AG	Patent maintained as amended
EP03743684A	May, 2011	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP02702247A	Dec, 2010	Sirna Therapeutics	Revoked
EP02702247A	Dec, 2010	Silence Therapeutics AG	Revoked
EP03732397A	Jan, 2010	Sanovel Ilac Sanayii ve Ticaret A.S.	Revoked
EP03732397A	Jan, 2010	KRKA, d.d., Novo mesto	Revoked
EP03732397A	Jan, 2010	Teva Pharmaceutical Industries Ltd.	Revoked
EP03732397A	Jan, 2010	Lupin Limited	Revoked
EP05002454A	Sep, 2009	Silence Therapeutics AG	Granted and Under Opposition
EP05002454A	Sep, 2009	ROQUES, Sarah Elizabeth	Granted and Under Opposition
EP05002454A	Sep, 2009	PFIZER LIMITED	Granted and Under Opposition
EP05002454A	Sep, 2009	Sanofi-Aventis Deutschland GmbH	Granted and Under Opposition
EP05002454A	Sep, 2009	Sirna Therapeutics	Granted and Under Opposition
EP03704413A	May, 2008	Mundipharma GmbH	Opposition procedure closed
EP02710786A	Feb, 2007	Sirna Therapeutics	Opposition rejected
EP02003683A	Mar, 2006	Abbott Laboratories	Patent maintained as amended
EP02003683A	Mar, 2006	atugen AG	Patent maintained as amended
EP02003683A	Mar, 2006	Quark Biotech, Inc.	Patent maintained as amended
EP02003683A	Mar, 2006	Sirna Therapeutics, Inc.	Patent maintained as amended
EP00910510A	May, 2003	AstraZeneca AB	Revoked
EP00910510A	May, 2003	Novartis AG	Revoked
EP00910510A	May, 2003	Isis Pharmaceuticals, Inc.	Revoked
EP00910510A	May, 2003	atugen AG	Revoked
EP00910510A	May, 2003	Aventis Pharma Deutschland GmbH	Revoked
EP00910510A	May, 2003	Grund, Martin, Dr.	Revoked
EP00910510A	May, 2003	JANSSEN PHARMACEUTICA N.V.	Revoked
EP00910510A	May, 2003	Sirna Therapeutics, Inc.	Revoked

Novartis's Family Patents

Novartis drugs have patent protection in a total of 75 countries. It's US patent count contributes only to 29.7% of its total global patent coverage. 13 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Novartis Drug List

Given below is the complete list of Novartis's drugs and the patents protecting them.

1. Afinitor

Afinitor is protected by 14 patents, out of which 11 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9006224	Neuroendocrine tumor treatment	01 Jul, 2028 (3 years from now)	Active
US8410131 (Pediatric)	Cancer treatment	01 May, 2026 (11 months from now)	Active
US8410131	Cancer treatment	01 Nov, 2025 (5 months from now)	Active
US8436010 (Pediatric)	Treatment of solid tumors with rapamycin derivatives	22 Aug, 2022 (2 years ago)	Expired
US8778962 (Pediatric)	Treatment of solid tumors with rapamycin derivatives	18 Aug, 2022 (2 years ago)	Expired
US8436010	Treatment of solid tumors with rapamycin derivatives	22 Feb, 2022 (3 years ago)	Expired
US8778962	Treatment of solid tumors with rapamycin derivatives	18 Feb, 2022 (3 years ago)	Expired
US7297703 (Pediatric)	Macrolides	06 Jun, 2020 (4 years ago)	Expired
US5665772 (Pediatric)	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	09 Mar, 2020 (5 years ago)	Expired
US7297703	Macrolides	06 Dec, 2019 (5 years ago)	Expired
US7741338	Macrolides	06 Dec, 2019 (5 years ago)	Expired
US5665772	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	09 Sep, 2019 (5 years ago)	Expired
US6004973 (Pediatric)	Pharmaceutical compositions comprising rafamycin coprecipitates	12 Jan, 2017 (8 years ago)	Expired
US6004973	Pharmaceutical compositions comprising rafamycin coprecipitates	12 Jul, 2016 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Afinitor's drug page

2. Alomide

Alomide is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5457126	Use of lodoxamide to treat ophthalmic allergic conditions	10 Oct, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alomide's drug page

3. Amturnide

Amturnide is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8183295	Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic	16 May, 2023 (1 year, 11 months ago)	Expired
US8618174	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	15 Nov, 2021 (3 years ago)	Expired
US5559111	δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides	21 Jul, 2018 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amturnide's drug page

4. Arcapta Neohaler

Arcapta Neohaler is protected by 5 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8479730	Inhaler device	11 Oct, 2028 (3 years from now)	Active
US6878721	Beta2-adrenoceptor agonists	25 Feb, 2025 (2 months ago)	Expired
US8067437	Beta-2-adrenoreceptor agonists	02 Jun, 2020 (4 years ago)	Expired
US8658673	BETA2-adrenoreceptor agonists	02 Jun, 2020 (4 years ago)	Expired
US8796307	Beta2-adrenoreceptor agonists	02 Jun, 2020 (4 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arcapta Neohaler's drug page

5. Coartem

Coartem is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5677331	Antimalarial compositions	14 Oct, 2014 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Coartem's drug page

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

6. Diovan

Diovan is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6294197 (Pediatric)	Solid oral dosage forms of valsartan	18 Dec, 2017 (7 years ago)	Expired
US6294197	Solid oral dosage forms of valsartan	18 Jun, 2017 (7 years ago)	Expired
US5972990 (Pediatric)	Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims	26 Apr, 2017 (8 years ago)	Expired
US5972990	Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims	26 Oct, 2016 (8 years ago)	Expired
US5399578 (Pediatric)	Acyl compounds	21 Sep, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diovan's drug page

7. Diovan Hct

Diovan Hct is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6294197 (Pediatric)	Solid oral dosage forms of valsartan	18 Dec, 2017 (7 years ago)	Expired
US6294197	Solid oral dosage forms of valsartan	18 Jun, 2017 (7 years ago)	Expired
US5399578 (Pediatric)	Acyl compounds	21 Sep, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diovan Hct's drug page

8. Emadine

Emadine is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5441958	Ophthalmic compositions comprising emedastine and methods for their use	08 Dec, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emadine's drug page

9. Entresto Sprinkle

Entresto Sprinkle is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10722471	Galenic formulations of organic compounds	02 Feb, 2037 (11 years from now)	Active
US8877938	Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations	27 May, 2027 (2 years from now)	Active
US9388134	Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations	08 Nov, 2026 (1 year, 5 months from now)	Active
US8101659	Methods of treatment and pharmaceutical composition	15 Jan, 2025 (3 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Entresto Sprinkle's drug page

10. Exelon

Exelon is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5602176	Phenyl carbamate	11 Feb, 2014 (11 years ago)	Expired
US4948807	Phenyl carbamates	14 Aug, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exelon's drug page

11. Exforge

Exforge is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6395728	Method of treatment and pharmaceutical composition	08 Jul, 2019 (5 years ago)	Expired
US6294197 (Pediatric)	Solid oral dosage forms of valsartan	18 Dec, 2017 (7 years ago)	Expired
US6294197	Solid oral dosage forms of valsartan	18 Jun, 2017 (7 years ago)	Expired
US5399578 (Pediatric)	Acyl compounds	21 Sep, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exforge's drug page

12. Exforge Hct

Exforge Hct is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8475839 (Pediatric)	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same	16 Nov, 2023 (1 year, 5 months ago)	Expired
US8101599	Pharmaceutical composition containing anti-hypertensive agents	16 May, 2023 (1 year, 11 months ago)	Expired
US8475839	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same	16 May, 2023 (1 year, 11 months ago)	Expired
US6294197 (Pediatric)	Solid oral dosage forms of valsartan	18 Dec, 2017 (7 years ago)	Expired
US6294197	Solid oral dosage forms of valsartan	18 Jun, 2017 (7 years ago)	Expired
US5399578 (Pediatric)	Acyl compounds	21 Sep, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exforge Hct's drug page

13. Exjade

Exjade is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6465504	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	05 Apr, 2019 (6 years ago)	Expired
US6596750	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	24 Jun, 2017 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exjade's drug page

14. Fabhalta

Fabhalta is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11951101	Methods of using factor B inhibitors	15 Jul, 2041 (16 years from now)	Active
US11603363	Crystalline form of LNP023	25 May, 2041 (16 years from now)	Active
US11723901	Uses of piperidinyl-indole derivatives	30 Aug, 2038 (13 years from now)	Active
US10093663	Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof	14 Jul, 2034 (9 years from now)	Active
US9682968	Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof	14 Jul, 2034 (9 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fabhalta's drug page

15. Famvir

Famvir is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5840763 (Pediatric)	Treatment of a latent infection of herpes viruses	01 Mar, 2016 (9 years ago)	Expired
US5916893 (Pediatric)	Treatment of a latent infection of herpes virus	01 Mar, 2016 (9 years ago)	Expired
US5840763	Treatment of a latent infection of herpes viruses	01 Sep, 2015 (9 years ago)	Expired
US5916893	Treatment of a latent infection of herpes virus	01 Sep, 2015 (9 years ago)	Expired
US5866581 (Pediatric)	Penciclovir for the treatment of post therapeutic neuralgia	04 Apr, 2015 (10 years ago)	Expired
US6124304 (Pediatric)	Penciclovir for the treatment of zoster associated pain	04 Apr, 2015 (10 years ago)	Expired
US5866581	Penciclovir for the treatment of post therapeutic neuralgia	04 Oct, 2014 (10 years ago)	Expired
US6124304	Penciclovir for the treatment of zoster associated pain	04 Oct, 2014 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Famvir's drug page

16. Foradil

Foradil is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6887459	Aerosol composition comprising formoterol	28 Nov, 2020 (4 years ago)	Expired
US6488027	Powder inhaler	08 Mar, 2019 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Foradil's drug page

17. Gilenya

Gilenya is protected by 11 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9592208 (Pediatric)	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	30 Sep, 2032 (7 years from now)	Active
US9592208	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	30 Mar, 2032 (6 years from now)	Active
US10543179	Dosage regimen of an S1P receptor modulator	25 Dec, 2027 (2 years from now)	Active
US9187405 (Pediatric)	S1P receptor modulators for treating relasping-remitting multiple sclerosis	25 Dec, 2027 (2 years from now)	Active
US9187405	S1P receptor modulators for treating relasping-remitting multiple sclerosis	25 Jun, 2027 (2 years from now)	Active
US8324283 (Pediatric)	Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol	29 Sep, 2026 (1 year, 4 months from now)	Active
US8324283	Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol	29 Mar, 2026 (10 months from now)	Active
US5604229 (Pediatric)	2-amino-1,3-propanediol compound and immunosuppressant	18 Aug, 2019 (5 years ago)	Expired
US5604229	2-amino-1,3-propanediol compound and immunosuppressant	18 Feb, 2019 (6 years ago)	Expired
US6004565	Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties	23 Sep, 2017 (7 years ago)	Expired
US5604229	2-amino-1,3-propanediol compound and immunosuppressant	18 Feb, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gilenya's drug page

18. Gleevec

Gleevec is protected by 12 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6958335 (Pediatric)	Treatment of gastrointestinal stromal tumors	19 Jun, 2022 (2 years ago)	Expired
US6958335	Treatment of gastrointestinal stromal tumors	19 Dec, 2021 (3 years ago)	Expired
US6894051 (Pediatric)	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	23 Nov, 2019 (5 years ago)	Expired
US7544799 (Pediatric)	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jul, 2019 (5 years ago)	Expired
USRE43932 (Pediatric)	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jul, 2019 (5 years ago)	Expired
US6894051	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	23 May, 2019 (5 years ago)	Expired
US7544799	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jan, 2019 (6 years ago)	Expired
USRE43932	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jan, 2019 (6 years ago)	Expired
USRE43932 (Pediatric)	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jan, 2019 (6 years ago)	Expired
USRE43932	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use	16 Jul, 2018 (6 years ago)	Expired
US5521184 (Pediatric)	Pyrimidine derivatives and processes for the preparation thereof	04 Jul, 2015 (9 years ago)	Expired
US5521184	Pyrimidine derivatives and processes for the preparation thereof	04 Jan, 2015 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gleevec's drug page

19. Izba

Izba is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8178582	Pharmaceutical compositions having desirable bioavailability	10 Oct, 2029 (4 years from now)	Active
US8722735	Pharmaceutical compositions having desirable bioavailability	10 Oct, 2029 (4 years from now)	Active
US8754123	Pharmaceutical compositions having desirable bioavailability	19 May, 2029 (4 years from now)	Active
US9144561	Pharmaceutical compositions having desirable bioavailability	13 Mar, 2029 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Izba's drug page

20. Jadenu Sprinkle

Jadenu Sprinkle is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6465504	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	05 Apr, 2019 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jadenu Sprinkle's drug page

21. Kisqali

Kisqali is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10799506	Ribociclib tablet	14 Apr, 2036 (10 years from now)	Active
US12064434	Ribociclib tablet	14 Apr, 2036 (10 years from now)	Active
US9193732	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	09 Nov, 2031 (6 years from now)	Active
US9868739	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	09 Nov, 2031 (6 years from now)	Active
US8415355	Pyrrolopyrimidine compounds and their uses	13 Mar, 2031 (5 years from now)	Active
US8685980	Pyrrolopyrimidine compounds and their uses	25 May, 2030 (5 years from now)	Active
US8962630	Pyrrolopyrimidine compounds and their uses	09 Dec, 2029 (4 years from now)	Active
US9416136	Pyrrolopyrimidine compounds and their uses	20 Aug, 2029 (4 years from now)	Active
US8324225	Pyrrolopyrimidine compounds and their uses	17 Jun, 2028 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kisqali's drug page

22. Kisqali Femara Co-pack (copackaged)

Kisqali Femara Co-pack (copackaged) is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10799506	Ribociclib tablet	14 Apr, 2036 (10 years from now)	Active
US12064434	Ribociclib tablet	14 Apr, 2036 (10 years from now)	Active
US9193732	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	09 Nov, 2031 (6 years from now)	Active
US9868739	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	09 Nov, 2031 (6 years from now)	Active
US8415355	Pyrrolopyrimidine compounds and their uses	13 Mar, 2031 (5 years from now)	Active
US8685980	Pyrrolopyrimidine compounds and their uses	25 May, 2030 (5 years from now)	Active
US8962630	Pyrrolopyrimidine compounds and their uses	09 Dec, 2029 (4 years from now)	Active
US9416136	Pyrrolopyrimidine compounds and their uses	20 Aug, 2029 (4 years from now)	Active
US8324225	Pyrrolopyrimidine compounds and their uses	17 Jun, 2028 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kisqali Femara Co-pack (copackaged)'s drug page

23. Leqvio

Leqvio is protected by 20 patents, out of which 11 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10851377	Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder	25 Aug, 2036 (11 years from now)	Active
US10125369	PCSK9 iRNA compositions and methods of use thereof	18 Aug, 2034 (9 years from now)	Active
US8106022	Carbohydrate conjugates as delivery agents for oligonucleotides	12 Dec, 2029 (4 years from now)	Active
US10806791	Carbohydrate conjugates as delivery agents for oligonucleotides	04 Dec, 2028 (3 years from now)	Active
US8828956	Carbohydrate conjugates as delivery agents for oligonucleotides	04 Dec, 2028 (3 years from now)	Active
US9370582	Carbohydrate conjugates as delivery agents for oligonucleotides	04 Dec, 2028 (3 years from now)	Active
US10131907	Glycoconjugates of RNA interference agents	24 Aug, 2028 (3 years from now)	Active
US8222222	Compositions and methods for inhibiting expression of the PCSK9 gene	29 Dec, 2027 (2 years from now)	Active
US8809292	Compositions and methods for inhibiting expression of the PCSK9 gene	10 May, 2027 (1 year, 11 months from now)	Active
US11530408	Therapeutic compositions	18 May, 2024 (11 months ago)	Expired
US10273477	Therapeutic compositions	08 Mar, 2024 (1 year, 2 months ago)	Expired
US10669544	Therapeutic compositions	08 Mar, 2024 (1 year, 2 months ago)	Expired
US9708615	Therapeutic compositions	08 Mar, 2024 (1 year, 2 months ago)	Expired
US9708610	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	01 Jan, 2024 (1 year, 4 months ago)	Expired
US10266825	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	04 Nov, 2023 (1 year, 6 months ago)	Expired
US11078485	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	04 Nov, 2023 (1 year, 6 months ago)	Expired
US8232383	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)	20 Feb, 2023 (2 years ago)	Expired
US10590418	Methods and compositions for RNAi mediated inhibition of gene expression in mammals	19 Jul, 2022 (2 years ago)	Expired
US8546143	Compositions and methods for inhibiting expression of a target gene	23 Apr, 2022 (3 years ago)	Expired
US9074213	Compositions and methods for inhibiting expression of a target gene	09 Mar, 2022 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Leqvio's drug page

24. Locametz

Locametz is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US12109277	Apparatus and method for penetrating and enlarging adjacent tissue layers	09 Mar, 2036 (10 years from now)	Active
US11369590	PSMA binding ligand-linker conjugates and methods for using	15 Aug, 2028 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Locametz's drug page

25. Mayzent

Mayzent is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11944602	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker	24 Jul, 2036 (11 years from now)	Active
US12071402	Immunosuppressant formulations	05 Jan, 2032 (6 years from now)	Active
US8492441	Dosage regimen of an S1P receptor agonist	30 Nov, 2030 (5 years from now)	Active
US7939519	Immunosuppresant compounds and compositions	27 Aug, 2028 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mayzent's drug page

26. Mekinist

Mekinist is protected by 18 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10869869 (Pediatric)	Method of adjuvant cancer treatment	28 Feb, 2034 (8 years from now)	Active
US10869869	Method of adjuvant cancer treatment	30 Aug, 2033 (8 years from now)	Active
US8580304 (Pediatric)	Pharmaceutical composition	28 Jul, 2032 (7 years from now)	Active
US9155706 (Pediatric)	Pharmaceutical composition	28 Jul, 2032 (7 years from now)	Active
US9271941 (Pediatric)	Pharmaceutical composition	28 Jul, 2032 (7 years from now)	Active
US9399021 (Pediatric)	Pharmaceutical composition	28 Jul, 2032 (7 years from now)	Active
US8580304	Pharmaceutical composition	28 Jan, 2032 (6 years from now)	Active
US9155706	Pharmaceutical composition	28 Jan, 2032 (6 years from now)	Active
US9271941	Pharmaceutical composition	28 Jan, 2032 (6 years from now)	Active
US9399021	Pharmaceutical composition	28 Jan, 2032 (6 years from now)	Active
US8703781 (Pediatric)	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	15 Apr, 2031 (5 years from now)	Active
US8952018 (Pediatric)	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	15 Apr, 2031 (5 years from now)	Active
US8703781	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	15 Oct, 2030 (5 years from now)	Active
US8952018	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	15 Oct, 2030 (5 years from now)	Active
US7378423 (Pediatric)	Pyrimidine compound and medical use thereof	29 Nov, 2027 (2 years from now)	Active
US7378423	Pyrimidine compound and medical use thereof	29 May, 2027 (2 years from now)	Active
US8835443 (Pediatric)	Pyrimidine compound and medical use thereof	10 Dec, 2025 (6 months from now)	Active
US8835443	Pyrimidine compound and medical use thereof	10 Jun, 2025 (29 days from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mekinist's drug page

27. Myfortic

Myfortic is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6306900	Enteric coated pharmaceutical compositions	27 Feb, 2018 (7 years ago)	Expired
US6025391	Enteric-coated pharmaceutical compositions of mycophenolate	10 Apr, 2017 (8 years ago)	Expired
US6172107	Entric-coated pharmaceutical compositions	10 Apr, 2017 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myfortic's drug page

28. Neoral

Neoral is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5985321	Soft gelatin capsule manufacture	26 Sep, 2014 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neoral's drug page

29. Patanase

Patanase is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7977376 (Pediatric)	Olopatadine formulations for topical nasal administration	02 Aug, 2023 (1 year, 9 months ago)	Expired
US8399508 (Pediatric)	Olopatadine formulations for topical nasal administration	17 Mar, 2023 (2 years ago)	Expired
US7977376	Olopatadine formulations for topical nasal administration	02 Feb, 2023 (2 years ago)	Expired
US8399508	Olopatadine formulations for topical nasal administration	17 Sep, 2022 (2 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Patanase's drug page

30. Piqray

Piqray is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8227462	Pyrrolidine-1,2-dicarboxamide derivatives	29 Apr, 2033 (7 years from now)	Active
US8476268	Pyrrolidine-1,2-dicarboxamide derivatives	10 Sep, 2029 (4 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Piqray's drug page

31. Pluvicto

Pluvicto is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US12208102	Methods of treating cancer	18 Sep, 2041 (16 years from now)	Active
US11951190	Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer	12 Nov, 2035 (10 years from now)	Active
US10398791	Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer	17 Oct, 2034 (9 years from now)	Active
US10406240	PSMA binding ligand-linker conjugates and methods for using	15 Aug, 2028 (3 years from now)	Active
US11318121	PSMA binding ligand-linker conjugates and methods for using	15 Aug, 2028 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pluvicto's drug page

32. Promacta

Promacta is protected by 28 patents, out of which 14 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8052993 (Pediatric)	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028 (2 years from now)	Active
US8052994 (Pediatric)	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028 (2 years from now)	Active
US8052995 (Pediatric)	3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028 (2 years from now)	Active
US8062665 (Pediatric)	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028 (2 years from now)	Active
US8071129 (Pediatric)	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028 (2 years from now)	Active
US8828430 (Pediatric)	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Feb, 2028 (2 years from now)	Active
US8052993	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027 (2 years from now)	Active
US8052994	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027 (2 years from now)	Active
US8052995	3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027 (2 years from now)	Active
US8062665	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027 (2 years from now)	Active
US8071129	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027 (2 years from now)	Active
US8828430	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	01 Aug, 2027 (2 years from now)	Active
US7547719 (Pediatric)	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	13 Jan, 2026 (8 months from now)	Active
US7547719	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	13 Jul, 2025 (2 months from now)	Active
US7795293 (Pediatric)	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	21 Nov, 2023 (1 year, 5 months ago)	Expired
US7795293	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	21 May, 2023 (1 year, 11 months ago)	Expired
US7160870 (Pediatric)	Thrombopoietin mimetics	20 May, 2023 (1 year, 11 months ago)	Expired
US7160870	Thrombopoietin mimetics	20 Nov, 2022 (2 years ago)	Expired
US7332481 (Pediatric)	Thrombopoietin mimetics	24 Nov, 2021 (3 years ago)	Expired
US7452874 (Pediatric)	Thrombopoietin mimetics	24 Nov, 2021 (3 years ago)	Expired
US7473686 (Pediatric)	Thrombopoietin mimetics	24 Nov, 2021 (3 years ago)	Expired
US7790704 (Pediatric)	Thrombopoietin mimetics	24 Nov, 2021 (3 years ago)	Expired
US7332481	Thrombopoietin mimetics	24 May, 2021 (3 years ago)	Expired
US7452874	Thrombopoietin mimetics	24 May, 2021 (3 years ago)	Expired
US7473686	Thrombopoietin mimetics	24 May, 2021 (3 years ago)	Expired
US7790704	Thrombopoietin mimetics	24 May, 2021 (3 years ago)	Expired
US6280959 (Pediatric)	Metal complexes	30 Apr, 2019 (6 years ago)	Expired
US6280959	Metal complexes	30 Oct, 2018 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Promacta's drug page

33. Promacta Kit

Promacta Kit is protected by 16 patents, out of which 14 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7547719 (Pediatric)	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	13 Jan, 2026 (8 months from now)	Active
US7547719	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	13 Jul, 2025 (2 months from now)	Active
US7795293 (Pediatric)	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	21 Nov, 2023 (1 year, 5 months ago)	Expired
US7795293	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	21 May, 2023 (1 year, 11 months ago)	Expired
US7160870 (Pediatric)	Thrombopoietin mimetics	20 May, 2023 (1 year, 11 months ago)	Expired
US7160870	Thrombopoietin mimetics	20 Nov, 2022 (2 years ago)	Expired
US7332481 (Pediatric)	Thrombopoietin mimetics	24 Nov, 2021 (3 years ago)	Expired
US7452874 (Pediatric)	Thrombopoietin mimetics	24 Nov, 2021 (3 years ago)	Expired
US7473686 (Pediatric)	Thrombopoietin mimetics	24 Nov, 2021 (3 years ago)	Expired
US7790704 (Pediatric)	Thrombopoietin mimetics	24 Nov, 2021 (3 years ago)	Expired
US7332481	Thrombopoietin mimetics	24 May, 2021 (3 years ago)	Expired
US7452874	Thrombopoietin mimetics	24 May, 2021 (3 years ago)	Expired
US7473686	Thrombopoietin mimetics	24 May, 2021 (3 years ago)	Expired
US7790704	Thrombopoietin mimetics	24 May, 2021 (3 years ago)	Expired
US6280959 (Pediatric)	Metal complexes	30 Apr, 2019 (6 years ago)	Expired
US6280959	Metal complexes	30 Oct, 2018 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Promacta Kit's drug page

34. Rydapt

Rydapt is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8575146	Pharmaceutical uses of staurosporine derivatives	02 Dec, 2030 (5 years from now)	Active
US7973031	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity	09 Oct, 2028 (3 years from now)	Active
US8222244	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity	29 Oct, 2022 (2 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rydapt's drug page

35. Sandostatin

Sandostatin is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5753618 (Pediatric)	Somatostatin analogue composition and use in treating breast cancer	19 Nov, 2015 (9 years ago)	Expired
US5753618	Somatostatin analogue composition and use in treating breast cancer	19 May, 2015 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sandostatin's drug page

36. Sandostatin Lar

Sandostatin Lar is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5922338 (Pediatric)	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	13 Jan, 2017 (8 years ago)	Expired
US5922682 (Pediatric)	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	13 Jan, 2017 (8 years ago)	Expired
US5922338	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	13 Jul, 2016 (8 years ago)	Expired
US5922682	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	13 Jul, 2016 (8 years ago)	Expired
US5688530 (Pediatric)	Sustained release formulations of water soluble peptides	18 May, 2015 (9 years ago)	Expired
US5639480 (Pediatric)	Sustained release formulations of water soluble peptides	17 Dec, 2014 (10 years ago)	Expired
US5688530	Sustained release formulations of water soluble peptides	18 Nov, 2014 (10 years ago)	Expired
US5639480	Sustained release formulations of water soluble peptides	17 Jun, 2014 (10 years ago)	Expired
US5538739 (Pediatric)	Sustained release formulations of water soluble peptides	23 Jan, 2014 (11 years ago)	Expired
US5538739	Sustained release formulations of water soluble peptides	23 Jul, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sandostatin Lar's drug page

37. Scemblix

Scemblix is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11407735	Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide	14 May, 2040 (15 years from now)	Active
US8829195	Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1	13 May, 2033 (8 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Scemblix's drug page

38. Seebri

Seebri is protected by 15 patents, out of which 13 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8182838	Dry powder composition comprising co-jet milled particles for pulmonary inhalation	20 Oct, 2028 (3 years from now)	Active
US8479730	Inhaler device	11 Oct, 2028 (3 years from now)	Active
US7736670	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US8048451	Pharmaceutical compositions for inhalation	27 Jun, 2021 (3 years ago)	Expired
US8303991	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US8435567	Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation	27 Jun, 2021 (3 years ago)	Expired
US8580306	Particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US8956661	Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof	27 Jun, 2021 (3 years ago)	Expired
US9931304	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US9962338	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US7229607	Treatment of respiratory disease	09 Apr, 2021 (4 years ago)	Expired
US8029768	Treatment of respiratory diseases	09 Apr, 2021 (4 years ago)	Expired
US6528678	Phosgene-free process for preparing carbamates	24 Apr, 2018 (7 years ago)	Expired
US6582678	Carrier particles for use in dry powder inhalers	24 Apr, 2018 (7 years ago)	Expired
US6521260	Carrier particles for use in dry powder inhalers	31 Jan, 2016 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Seebri's drug page

39. Starlix

Starlix is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6559188	Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes	15 Sep, 2020 (4 years ago)	Expired
US6878749	Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes	15 Sep, 2020 (4 years ago)	Expired
US6641841	Tablet composition	14 Nov, 2017 (7 years ago)	Expired
US6844008	Tablet composition	14 Nov, 2017 (7 years ago)	Expired
US5488150	Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them	30 Jan, 2013 (12 years ago)	Expired
US5463116	Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them	21 Oct, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Starlix's drug page

40. Tafinlar

Tafinlar is protected by 16 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11504333 (Pediatric)	Pharmaceutical composition	29 Dec, 2038 (13 years from now)	Active
US11504333	Pharmaceutical composition	29 Jun, 2038 (13 years from now)	Active
US10869869 (Pediatric)	Method of adjuvant cancer treatment	28 Feb, 2034 (8 years from now)	Active
US10869869	Method of adjuvant cancer treatment	30 Aug, 2033 (8 years from now)	Active
US8703781 (Pediatric)	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	15 Apr, 2031 (5 years from now)	Active
US8952018 (Pediatric)	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	15 Apr, 2031 (5 years from now)	Active
US8703781	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	15 Oct, 2030 (5 years from now)	Active
US8952018	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	15 Oct, 2030 (5 years from now)	Active
US7994185 (Pediatric)	Benzene sulfonamide thiazole and oxazole compounds	20 Jul, 2030 (5 years from now)	Active
US8415345 (Pediatric)	Benzene sulfonamide thiazole and oxazole compounds	20 Jul, 2030 (5 years from now)	Active
US7994185	Benzene sulfonamide thiazole and oxazole compounds	20 Jan, 2030 (4 years from now)	Active
US8415345	Benzene sulfonamide thiazole and oxazole compounds	20 Jan, 2030 (4 years from now)	Active
US9233956 (Pediatric)	Benzene sulfonamide thiazole and oxazole compounds	04 Nov, 2029 (4 years from now)	Active
US9233956	Benzene sulfonamide thiazole and oxazole compounds	04 May, 2029 (3 years from now)	Active
US8835443 (Pediatric)	Pyrimidine compound and medical use thereof	10 Dec, 2025 (6 months from now)	Active
US8835443	Pyrimidine compound and medical use thereof	10 Jun, 2025 (29 days from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tafinlar's drug page

41. Tasigna

Tasigna is protected by 14 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9061029 (Pediatric)	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	07 Oct, 2032 (7 years from now)	Active
US9061029	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	07 Apr, 2032 (6 years from now)	Active
US8163904 (Pediatric)	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide	23 Feb, 2029 (3 years from now)	Active
US8163904	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide	23 Aug, 2028 (3 years from now)	Active
US8293756 (Pediatric)	Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate	25 Mar, 2028 (2 years from now)	Active
US8293756	Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate	25 Sep, 2027 (2 years from now)	Active
US8389537 (Pediatric)	Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	18 Jan, 2027 (1 year, 8 months from now)	Active
US8415363 (Pediatric)	Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	18 Jan, 2027 (1 year, 8 months from now)	Active
US8501760 (Pediatric)	Pharmaceutical compositions comprising nilotinib or its salt	18 Jan, 2027 (1 year, 8 months from now)	Active
US8389537	Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	18 Jul, 2026 (1 year, 2 months from now)	Active
US8415363	Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	18 Jul, 2026 (1 year, 2 months from now)	Active
US8501760	Pharmaceutical compositions comprising nilotinib or its salt	18 Jul, 2026 (1 year, 2 months from now)	Active
US7169791 (Pediatric)	Inhibitors of tyrosine kinases	04 Jan, 2024 (1 year, 4 months ago)	Expired
US7169791	Inhibitors of tyrosine kinases	04 Jul, 2023 (1 year, 10 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tasigna's drug page

42. Tekamlo

Tekamlo is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8613949	Galenical formulations of organic compounds	21 Dec, 2029 (4 years from now)	Active
US5559111	δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides	21 Jul, 2018 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tekamlo's drug page

43. Trileptal

Trileptal is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8119148 (Pediatric)	Suspension comprising oxcarbazepine	19 Jun, 2021 (3 years ago)	Expired
US8119148	Suspension comprising oxcarbazepine	19 Dec, 2020 (4 years ago)	Expired
US7037525 (Pediatric)	Oxacarbazepine film-coated tablets	12 Aug, 2018 (6 years ago)	Expired
US7037525	Oxacarbazepine film-coated tablets	12 Feb, 2018 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trileptal's drug page

44. Tykerb

Tykerb is protected by 7 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8821927	Pharmaceutical composition	18 Sep, 2029 (4 years from now)	Active
US7157466	Quinazoline ditosylate salt compounds	19 Nov, 2021 (3 years ago)	Expired
US6713485	Heterocyclic compounds	29 Sep, 2020 (4 years ago)	Expired
US6727256	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors	08 Jan, 2019 (6 years ago)	Expired
US8513262	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors	08 Jan, 2019 (6 years ago)	Expired
US6391874	Fused heterocyclic compounds as protein tyrosine kinase inhibitors	11 Jul, 2017 (7 years ago)	Expired
US6828320	Heterocyclic compounds	11 Jul, 2017 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tykerb's drug page

45. Tyzeka

Tyzeka is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7589079	Crystalline and amorphous forms of beta-L-2′-deoxythymidine	11 Sep, 2023 (1 year, 7 months ago)	Expired
US7858594	Crystalline and amorphous forms of beta-L-2′-deoxythymidine	11 Sep, 2023 (1 year, 7 months ago)	Expired
US6569837	β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B	25 Oct, 2020 (4 years ago)	Expired
US6395716	β-L-2′-deoxy-nucleosides for the treatment of hepatitis B	10 Aug, 2019 (5 years ago)	Expired
US6444652	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B	10 Aug, 2019 (5 years ago)	Expired
US6566344	β-L-2′-deoxy-nucleosides for the treatment of hepatitis B	10 Aug, 2019 (5 years ago)	Expired
US7795238	β-L-2′-deoxy-nucleosides for the treatment of hepatitis B	10 Aug, 2019 (5 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tyzeka's drug page

46. Utibron

Utibron is protected by 20 patents, out of which 18 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8182838	Dry powder composition comprising co-jet milled particles for pulmonary inhalation	20 Oct, 2028 (3 years from now)	Active
US8479730	Inhaler device	11 Oct, 2028 (3 years from now)	Active
US6878721	Beta2-adrenoceptor agonists	25 Feb, 2025 (2 months ago)	Expired
US7736670	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US8048451	Pharmaceutical compositions for inhalation	27 Jun, 2021 (3 years ago)	Expired
US8303991	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US8435567	Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation	27 Jun, 2021 (3 years ago)	Expired
US8580306	Particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US8956661	Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof	27 Jun, 2021 (3 years ago)	Expired
US9931304	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US9962338	Method of making particles for use in a pharmaceutical composition	27 Jun, 2021 (3 years ago)	Expired
US7229607	Treatment of respiratory disease	09 Apr, 2021 (4 years ago)	Expired
US8029768	Treatment of respiratory diseases	09 Apr, 2021 (4 years ago)	Expired
US7820694	Beta-2-adrenoreceptor agonists	02 Jun, 2020 (4 years ago)	Expired
US8067437	Beta-2-adrenoreceptor agonists	02 Jun, 2020 (4 years ago)	Expired
US8283362	Beta-2-adrenoreceptor agonists	02 Jun, 2020 (4 years ago)	Expired
US8658673	BETA2-adrenoreceptor agonists	02 Jun, 2020 (4 years ago)	Expired
US8796307	Beta2-adrenoreceptor agonists	02 Jun, 2020 (4 years ago)	Expired
US6582678	Carrier particles for use in dry powder inhalers	24 Apr, 2018 (7 years ago)	Expired
US6521260	Carrier particles for use in dry powder inhalers	31 Jan, 2016 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Utibron's drug page

47. Valturna

Valturna is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8168616	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension	03 Jul, 2026 (1 year, 1 month from now)	Active
US5559111	δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides	21 Jul, 2018 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valturna's drug page

48. Vijoice

Vijoice is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8227462	Pyrrolidine-1,2-dicarboxamide derivatives	29 Apr, 2033 (7 years from now)	Active
US8476268	Pyrrolidine-1,2-dicarboxamide derivatives	10 Sep, 2029 (4 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vijoice's drug page

49. Vitravene Preservative Free

Vitravene Preservative Free is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5442049	Oligonucleotides for modulating the effects of cytomegalovirus infections	15 Aug, 2012 (12 years ago)	Expired
US5595978	Composition and method for treatment of CMV retinites	15 Aug, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vitravene Preservative Free's drug page

50. Votrient

Votrient is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7105530	Pyrimidineamines as angiogenesis modulators	19 Oct, 2023 (1 year, 6 months ago)	Expired
US7262203	Pyrimidineamines as angiogenesis modulators	19 Dec, 2021 (3 years ago)	Expired
US8114885	Chemical compounds	19 Dec, 2021 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Votrient's drug page

51. Zometa

Zometa is protected by 5 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7932241	Pharmaceutical products comprising bisphosphonates	05 Feb, 2028 (2 years from now)	Active
US8324189 (Pediatric)	Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases	29 Nov, 2025 (6 months from now)	Active
US8324189	Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases	29 May, 2025 (17 days from now)	Active
US4939130 (Pediatric)	Substituted alkanediphosphonic acids and pharmaceutical use	02 Mar, 2013 (12 years ago)	Expired
US4939130	Substituted alkanediphosphonic acids and pharmaceutical use	02 Sep, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zometa's drug page

52. Zortress

Zortress is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5665772 (Pediatric)	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	09 Mar, 2020 (5 years ago)	Expired
US5665772	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	09 Sep, 2019 (5 years ago)	Expired
US6239124 (Pediatric)	Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin	11 Feb, 2018 (7 years ago)	Expired
US6455518 (Pediatric)	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin	29 Jan, 2018 (7 years ago)	Expired
US6239124	Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin	11 Aug, 2017 (7 years ago)	Expired
US6455518	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin	29 Jul, 2017 (7 years ago)	Expired
US6004973 (Pediatric)	Pharmaceutical compositions comprising rafamycin coprecipitates	12 Jan, 2017 (8 years ago)	Expired
US6004973	Pharmaceutical compositions comprising rafamycin coprecipitates	12 Jul, 2016 (8 years ago)	Expired
US6440990 (Pediatric)	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	24 Mar, 2014 (11 years ago)	Expired
US6440990	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants	24 Sep, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zortress's drug page

53. Zykadia

Zykadia is protected by 13 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8703787	Methods of using ALK inhibitors	02 Feb, 2032 (6 years from now)	Active
US9309229	Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine	18 Jan, 2032 (6 years from now)	Active
US8039474	2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists	29 Jun, 2030 (5 years from now)	Active
US8039479	Compounds and compositions as protein kinase inhibitors	29 Jun, 2030 (5 years from now)	Active
US7964592	2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders	29 Apr, 2028 (2 years from now)	Active
US8377921	Compounds and compositions as protein kinase inhibitors	20 Nov, 2027 (2 years from now)	Active
US8399450	Compounds and compositions as protein kinase inhibitors	20 Nov, 2027 (2 years from now)	Active
US7893074	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders	25 Apr, 2026 (11 months from now)	Active
US8188276	2,4-pyrimidinediamine compounds and their uses	31 Jan, 2023 (2 years ago)	Expired
US8835430	2,4-pyrimidinediamine compounds and their uses	31 Jan, 2023 (2 years ago)	Expired
US9018204	2,4-pyrimidinediamine compounds and their uses	31 Jan, 2023 (2 years ago)	Expired
US9416112	2,4-pyrimidinediamine compounds and their uses	31 Jan, 2023 (2 years ago)	Expired
US7153964	Pyrimidine compounds	26 Feb, 2021 (4 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zykadia's drug page

Pharsight

Pharsight

Latest Legal Activities on Novartis's Drug Patents

Novartis's Drug Patent Litigations

Novartis Drug Patents' Oppositions Filed in EPO

Novartis's Family Patents

Novartis Drug List

Explore Our Curated Drug Screens

Novartis News

Related content

Have Questions?